Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 14Carcinoma, Non-Small-Cell Lung 9Neoplasm Metastasis 7Breast Neoplasms 7Melanoma 5Lymphoma, Non-Hodgkin 3Lymphoma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Carcinoma 3Solid Tumor 2Recurrence 2Prostatic Neoplasms 2Gastrointestinal Stromal Tumors 2Advanced Solid Tumor 2Advanced Malignancies 2cMET-dysregulated Advanced Solid Tumors 1Urothelial Cancer 1Thyroid Neoplasms 1Synovitis, Pigmented Villonodular 1Solid Tumours 1Solid Tumour 1Solid Tumors, KRAS Mutation 1Solid Tumors 1Solid Tumor, Adult 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Prostate Cancer Patients 1

Interventions

Midazolam 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solid Tumors, KRAS Mutation × Midazolam × Clear all
NCT04973163 2026-02-17

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

Boehringer Ingelheim

Phase 1 Active not recruiting
30 enrolled
Other solid neoplasm

Solid Tumors, KRAS Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡